Tag: CVA
-
2018 Emerging Drug Litigations: Viberzi and Actemra
Additional information concerning the potentially harmful side effects of Viberzi and Actemra was released over the course of 2017, and we will continue to monitor the situation in 2018.
-
Farxiga / Jardiance / Invokana Safety As Regards Diabetic Ketoacidosis Now Being Studied By Health Canada In Addition To Current FDA Investigation
Institute For Safe Medication Practices Signal For Invokana Kidney Failure Risks Seems To Apply To Farxiga, Jardiance, And Other SGLT2 Diabetes Drugs Also (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada…
-
Multaq: Increased Risks Of Side Effects, Including Death, Outweigh Any Benefits Say Researchers Who Reviewed Clinical Data
In Addition, They Are Highly Critical Of Relationship The Sanofi Aventis Drug Company Had With Those Doctors Who Developed Prescribing Guidelines (Posted by Tom Lamb at DrugInjuryWatch.com)As we know, now, since being approved by the FDA…
-
Merck’s NuvaRing Increases The Relative Risk For Blood-Clot Side Effects Says Medical Expert After Weighing Competing Studies
And Another Medical Journal Article Concludes Venous Thromboembolism (VTE) Risk Associated With NuvaRing Is As High As YAZ Or Yasmin And Ortho Evra (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2012 I wrote…
-
Women Who Used YAZ / Yasmin / Ocella Are Getting Letters From Aetna Medical Insurance Company
Here Is Why Aetna Wants To Know Whether You Have Filed A Gallbladder Or A Blood Clot Lawsuit Against Bayer (Posted by Tom Lamb at DrugInjuryWatch.com) We have learned that women who took the birth…
-
YAZ / Yasmin / Ocella: FDA Study Suggests An Increased Risk Of Blood Clots That Can Cause Side Effects Like Pulmonary Embolism
Early Results Suggest An Approximately 1.5-fold Increase In The Risk For Birth Control Pills With Drospirenone (DRSP) (Posted by Tom Lamb at DrugInjuryWatch.com) _____________________________________________________________________ UPDATE: YAZ / Yasmin / Ocella Update: October 2011 FDA…
-
November 2009 Medical Journal Article Describes Large Ongoing Study About Safety Of YAZ
INAS-OC Study: Intended To Evaluate Risk Of Developing Cardiovascular Side Effects For Women Who Use YAZ (DRSP/EE 24d) (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2009 we first wrote about the International Active…